GlassScriptPhysician profile
Heather R Pierce
NPI 1992330583
$72,077.94
in general payments reported to CMS, 2019-2025
35 companies · $29K in 2025
The $29K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,991 · 2023: $20K · 2024: $19K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $57K · Travel and Lodging: $7,865 · Food and Beverage: $4,722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,500.00 |
| Travel and Lodging | $7,864.73 |
| Food and Beverage | $4,722.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $70,240.88 | 2022-2025 | Imfinzi, Lynparza, Enhertu |
| Novartis Pharmaceuticals Corporation | $185.64 | 2022-2023 | |
| Seagen INC. | $172.61 | 2022-2023 | Adcetris, Padcev |
| E.R. Squibb & Sons, L.L.C. | $149.75 | 2022-2023 | Pomalyst |
| Abbvie INC. | $137.86 | 2022 | |
| Celgene Corporation | $111.07 | 2022-2023 | Pomalyst |
| Glaxosmithkline, LLC. | $92.34 | 2022-2023 | Jemperli, Zejula |
| Merck Sharp & Dohme LLC | $81.40 | 2022-2023 | Welireg, Keytruda, Lynparza |
| Pharmacyclics LLC, An Abbvie Company | $71.28 | 2022-2023 | Imbruvica |
| Janssen Biotech, INC. | $64.37 | 2022-2023 | Erleada |
| Eisai INC. | $63.82 | 2022-2023 | |
| Incyte Corporation | $58.66 | 2022 | |
| Genentech USA, INC. | $58.11 | 2022-2023 | Gavreto, Tecentriq, Alecensa |
| Lilly USA, LLC | $57.05 | 2022-2023 | Verzenio |
| Bayer Healthcare Pharmaceuticals INC. | $52.57 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $47.95 | 2022 | |
| Daiichi Sankyo INC. | $46.86 | 2022 | |
| Pfizer INC. | $40.51 | 2022 | |
| G1 Therapeutics, INC. | $32.77 | 2022-2023 | Cosela |
| Servier Pharmaceuticals LLC | $32.31 | 2022 | |
| Organon LLC | $30.42 | 2022 | |
| Sobi, INC | $29.41 | 2023 | |
| Aveo Pharmaceuticals, INC. | $28.78 | 2022 | |
| Mirati Therapeutics, INC. | $21.81 | 2023 | Krazati |
| Beigene USA, INC. | $19.51 | 2022 | |
| Stemline Therapeutics INC. | $18.91 | 2023 | Orserdu |
| Eusa Pharma (US) LLC | $16.39 | 2022 | |
| Genzyme Corporation | $16.39 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $16.37 | 2022 | |
| Alexion Pharmaceuticals, INC. | $15.49 | 2022 | |
| Coherus Oncology, INC. | $14.77 | 2022 | |
| Gilead Sciences, INC. | $13.65 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $13.56 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.86 | 2022 | |
| Jazz Pharmaceuticals INC. | $11.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.